The US Food and Drug Administration (FDA) has detailed its thinking on how and when it is acceptable to conduct first-in-human (FIH) trials of drugs with mutagenic potential. The agency takes a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results